A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease. by Scott, J et al.
UN
CO
RR
EC
TE
D 
PR
OO
FS
BJR © 2016 The Authors. Published by the British Institute of Radiology
Received:
19 November 2015
Revised:
3 February 2016
Accepted:
15 February 2016
http://dx.doi.org/10.1259/bjr.20150979
Cite this article as:
Scott J, Underwood J, Garvey LJ, Mora-Peris B, Winston A. A comparison of two post-processing analysis methods to quantify cerebral
metabolites measured via proton magnetic resonance spectroscopy in HIV disease. Br J Radiol 2016; 89: 20150979.
SHORT COMMUNICATION
A comparison of two post-processing analysis methods to
quantify cerebral metabolites measured via proton
magnetic resonance spectroscopy in HIV disease
JOSEPH SCOTT, BSc, JONATHAN UNDERWOOD, MBBS, BSc, MRCP, LUCY J GARVEY, MD(Res), MRCP, MBChB,
BORJA MORA-PERIS, LMS, MSc, DTM&H and ALAN WINSTON, MBChB, MD, FRCP1
Division of Infectious Diseases, Winston Churchill Wing, St Mary’s Campus, Imperial College, London, UK
Address correspondence to: Dr Jonathan Underwood
E-mail: jonathan.underwood@imperial.ac.uk2 3
Objective: Non-invasive biomarkers to monitor cerebral
function in treated human immunodeficiency virus (HIV)
disease are required. Cerebral metabolite ratios (CMRs)
measured by proton-MR spectroscopy (1H-MRS) are
a potential biomarker. Here, we compare two post-
processing software packages to quantify CMRs.
Methods: Cerebral 1H-MRS data from 11 HIV-positive subjects
before and after antiretroviral therapy intensification with
maraviroc were quantified using a java-based version of the
MR user interface package (jMRUI) and4 the totally automatic
robust quantitation in nuclear MR (TARQUIN). 1H-MRS data
included N-acetylaspartate (NAA), creatine (Cr), choline
(Cho) and myo-inositol (mI) from three cerebral locations.
Differences in quantification and clinical associations of
CMRs measured by the two packages were evaluated.
Results: Mean CMRs were generally lower when mea-
sured by TARQUIN than by jMRUI (NAA/Cr, Cho/Cr, mI/
Cr ratios of 1.78, 0.83, 0.81 for jMRUI, and 1.27, 0.25, 0.81
for TARQUIN). Longitudinal changes were observed in
CMRs in the basal ganglia voxel although these changes
were not statistically significant [17.1% (p50.18), 10.0%
(p50.91) and 26.6% (p50.61) and 114.8% (p50.18), 1
17.9% (p50.07) and 134.8% (p50.17) for NAA/Cr,
Cho/Cr and mI/Cr ratios measured by TARQUIN and
jMRUI, respectively]. Plasma maraviroc concentration
was associated with a decrease in mI/Cr ratio measured
via TARQUIN (p50.049).
Conclusion: Although CMRs differed when quantified by
jMRUI vs TARQUIN, these differences were consistently
observed across three cerebral locations, and clinical
associations were evident by both methods.
Advances in knowledge: TARQUIN and jMRUI are viable
options to use in the post-processing of cerebral MRS
data acquired in HIV disease.
INTRODUCTION
30 years since its emergence, human immunodeﬁciency
virus-1 (HIV-1) infection remains a global healthcare issue
affecting 35 million individuals worldwide, with 2.3 million
new infections reported in 2012.1 Before the advent of
combination antiretroviral therapy (cART), HIV-
associated dementia affected between 5% and 20% of
patients, with an annual incidence of new diagnosis of 7%
among individuals with acquired immune deﬁciency
syndrome.2 The widespread use of cART has seen sig-
niﬁcant reductions in HIV-associated morbidity and
mortality, with patients now beneﬁting from longer and
healthier lives.3 Although incidence rates for HIV-
associated dementia have declined, the prevalence of
mild to moderate forms of cognitive dysfunction
remains high,4 with neuropsychological deﬁcits reported
in 15–50% of patients despite long-term cART and
suppression of viraemia.5
Rapid, sensitive and reliable screening tool for the presence
of HIV-associated cognitive disorders are needed. Speciﬁc
bedside tools such as the HIV dementia scale and the In-
ternational HIV Dementia Scale have been shown to lack
diagnostic effectiveness owing to inconsistencies in lan-
guage comprehension and confounding clinical parame-
ters.6 Furthermore, potential plasma biomarkers have
shown little speciﬁcity in detecting HIV-associated cogni-
tive disorders.7 Although cerebrospinal ﬂuid (CSF) mark-
ers are considered a more valuable clinical tool,8 the
requirement for CSF examination is challenging, and less
invasive methods are preferable. Measurement of cerebral
metabolites as biomarkers, via proton-MR spectroscopy
(1H-MRS), is one attractive approach for the assessment of
cerebral function in HIV disease.
1H-MRS is a non-invasive method of analysing metabolite
concentrations in targeted anatomical locations, and
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abnormalities have been correlated with clinical disease status in
large case series which have adequate power to detect such
associations. N-acetylaspartate (NAA), myo-inositol (mI) and
choline (Cho)-containing compounds are measured to reﬂect
neuronal damage and inﬂammation that are reported to be al-
tered in HIV infection.9 A reduction in the neuronal marker
NAA has been correlated with the presence of dementia in HIV-
infected individuals and with the clinical severity of this de-
mentia.10 Elevated levels of both mI and Cho, representing
neuroinﬂammation, have been reported in neurologically
symptomatic patients with HIV infection.11
The scope of 1H-MRS in clinical medicine is expanding,12 but
the use of this method requires accurate post-acquisition
quantiﬁcation of the 1H-MRS spectra.13 Prior work has been
undertaken to compare the sensitivity of quantiﬁcation methods
over a range of diseased states,14,15 but to our knowledge, no
comparisons have been made of quantiﬁcation models in the
analysis of cerebral metabolites in HIV disease. Although such
comparisons should not differ in HIV disease compared with
other disease states, data on the utility of these software packages
within the speciﬁc disease area provides clinical researchers with
the conﬁdence to use such modalities within a clinical research
setting. The aim of this study is to directly compare two 1H-MRS
analysis models and to identify any differences present in cere-
bral metabolite ratios (CMRs) in HIV-positive individuals.
METHODS AND MATERIALS
Subject selection
Eligible individuals were neurologically asymptomatic adults
with chronic HIV-infection, receiving tenofovir/emtricitabine/
lopinavir/ritonavir as antiretroviral therapy with plasma HIV
RNA levels of ,50 copies/ml (Bayer Quantiplex Assay™5 ) for at
least 3 months prior to study entry. Cerebral 1H-MRS imaging
was undertaken prior to antiretroviral intensiﬁcation with
maraviroc (baseline scan) and after 14 days of antiretroviral
intensiﬁcation with maraviroc (follow-up scan). Results from
this study have previously been published.16 Here, we report
differences in CMRs within this antiretroviral intensiﬁcation
study measured by two methods. Local human ethical approval
was obtained (Imperial College Healthcare National Health
Service Trust local ethics approval), and all subjects provided
written informed consent prior to undertaking any study
procedures.
Cerebral proton-MR spectroscopy
1H-MRS imaging was performed on a Phillips Achieva™ 1.5-T
scanner (Phillips NV, Best, Netherlands) at Hammersmith
Hospital, London, UK. To ensure accurate positioning of the
voxels, T1 weighted MR images of the brain were performed in
the sagittal, coronal and axial planes, and T2 weighted images
were obtained to exclude any visible cerebral pathology. An MR
spectroscopy (MRS) operations manual was used to ensure all
MRS examinations were undertaken using identical operational
settings. An experienced radiographer selected voxel locations
using a standardized procedure ensuring consistent voxel posi-
tioning across subjects. Voxels were placed on areas of the brain
which appeared anatomically normal on T1 and T2 images.
1H-MRS data were acquired by single-voxel examination in three
locations: mid-frontal grey matter, right frontal white matter
(FWM) and the right basal ganglia (RBG). Voxel size was ap-
proximately 5.5 cm3 (1.753 1.753 1.75 cm). Spectra were
obtained using a double spin-echo point-resolved spectroscopy
sequence with the following settings: echo time, 36ms; repeti-
tion time, 3000ms; 2048 data points; spectral width, 2500Hz;
and 128 data acquisitions. Cerebral metabolites NAA, mI and
Cho were measured and expressed as ratios to creatine (Cr). All
spectra were inspected visually by an experienced physicist to
ensure quality of acquisition, and in cases with low signal-to-
noise ratio, acquisition was repeated.
Cerebrospinal fluid analysis
Lumbar puncture examination was performed using aseptic
technique. Maraviroc concentrations were measured in CSF
samples at the University of Liverpool, UK, using
high-performance liquid chromatography–tandem mass
spectrometry.17
Analysis models
MR spectra were analysed and quantiﬁed using two programs:
a java-based version of the MR user interface package
(jMRUI v. 5.0 6)18 and the totally automatic robust quantita-
tion in nuclear MR (TARQUIN) algorithm.19 These were
chosen because jMRUI has been used previously by our group
and others to quantify CMRs in HIV disease. TARQUIN is a new
algorithm, that to our knowledge has not been used to quantify
CMRs in HIV disease. It offers several potential advantages over
jMRUI and LCmodel, another widely used software package,
namely it is free to use and modify under the General Public 7
License, is available across computer platforms and is designed
to give rapid and automated quantitation of CMRs. jMRUI
enables time domain analysis of in vivo MRS data in two stages.
Pre-processing requires user interaction largely to suppress re-
sidual water molecules using the HLSVD/HLSVDPro ﬁlters 820
and the use of the Cadzow function to ﬁlter the signal.18 This
manual pre-processing step may inﬂuence the results of model
ﬁtting and thus affect the accuracy of signal quantiﬁcation.13
Quantitation of MR spectra utilizes the AMARES 9algorithm,
10
20
requiring the input of prior knowledge to estimate peak fre-
quency and decay constants.21 The same prior knowledge of the
estimated peaks was inputted for all analyses in this study with
peaks set at the following positions; 2.0 parts per million (ppm)
and 3.9 line width [LW (Hz)] for NAA, 3.01 ppm and 4.9 LW for
Cr, 3.2 ppm and 4.9 LW for Cho and 3.54 ppm and 4.9 LW for
mI. An example spectra being read by jMRUI is provided in
Figure 1a.
TARQUIN (v. 4.3.2) is a novel time domain–ﬁtting algorithm
used to quantify 1H-MRS data.19 A least squares approach
similar to the AQSES algorithm22 is used to estimate signal
amplitudes, yet TARQUIN imposes a new method of soft con-
straints on the projection to reduce errors associated with
overﬁtting.19 Baseline interference is reduced by point trunca-
tion and HSVD water removal23 in a fully automated process,
and thus user variability is eliminated. Point truncation elimi-
nates the very early points of the free induction decay that
contains very broad signals that are difﬁcult to model and the
last few that contain only noise. An example spectra being read
BJR Scott et al
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Figure 1. Examples of MRS spectra. (a) Original signal (bottom) and jMRUI model (top). (b) Original signal (black14 ), TARQUIN model
(red) with individual peaks (green). Cho, choline; Cr, creatine, jMRUI, java-based version of the MR user interface; NAA,
N-acetylaspartate; mI, myo-inositol; ppm, parts per million; TARQUIN, totally automatic robust quantitation in nuclear MR.
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by TARQUIN can be seen in Figure 1b. This algorithm has been
found to compare favourably with LCmodel using both clinical and
simulated data.19 Cerebral metabolites NAA, mI and Cho were
quantiﬁed by both methods and expressed as ratios to cerebral Cr.
Statistical analysis
All statistical analyses were performed using SPSS® v. 21.0 (IBM
Corp., New York, NY; formerly SPSS Inc., Chicago, IL). CMRs
were evaluated using paired sample t-tests to compare jMRUI
with TARQUIN. Absolute changes in CMRs between baseline
and Day 14 were evaluated using paired sample t-tests. Linear
regression analyses were used to assess the correlation between
changes in CMRs over the study period with pharmacokinetic
parameters measured in this study (maraviroc plasma and CSF
concentration) with no correction for multiple comparisons as
CMRs are correlated to some degree. p-values ,0.05 were
considered statistically signiﬁcant.
RESULTS
1H-MRS quantification comparing jMRUI and
TARQUIN analysis models 11
A comparison of all CMRs from both study time points by
anatomical region, quantiﬁed by the two analysis models is
shown in Figure 2. CMRs were signiﬁcantly higher for NAA/Cr
and Cho/Cr when quantiﬁed via jMRUI across all three voxels.
Coefﬁcients of variation (CoVs) and 95% conﬁdence intervals
Figure 2. Box plots of cerebral metabolite ratios quantified using java-based version of the MR user interface (jMRUI) and totally
automatic robust quantitation in nuclear MR (TARQUIN) by anatomical region (includes Day 0 and Day 14 data). Box plots show
median values (solid horizontal lines), interquartile range (IQR, box), 1.53 IQR (vertical lines) and outlier values (solid circles).
p-values computed using the paired t-test. BG, basal ganglia; FG, frontal grey; FW, frontal white; NAA, N-acetylaspartate15 .
O
N
L
IN
E
C
O
L
O
R
O
N
L
Y
Table 1. Coefficients of variation (95% confidence intervals) for each cerebral metabolite ratio by voxel and algorithm
Voxel location Algorithm
Cerebral metabolite ratio
NAA/Cr Cho/Cr mI/Cr
Frontal grey matter
TARQUIN 25.5 (17.5–47.2) 16.2 (11.3–29.1) 24.1 (16.6–44.4)
jMRUI 10.8 (7.5–20.0) 14.9 (10.2–27.8) 52.4 (33.8–121)
Frontal white matter
TARQUIN 21.2 (14.7–38.7) 13.5 (9.4–24.1) 30.7 (20.9–58.1)
jMRUI 11.8 (8.2–20.9) 20.9 (14.4–37.9) 59.7 (38.6–138)
Right basal ganglia
TARQUIN 15.2 (10.6–27.3) 13.3 (9.2–23.6) 39.0 (26.2–77.1)
jMRUI 21.2 (14.6–38.7) 14.8 (10.3–26.5) 72.9 (45.6–192)
Cho, choline; Cr, creatine; jMRUI, java-based version of the MR user interface; mI, myo-inositol; NAA, N-acetylaspartate; TARQUIN, totally automatic
robust quantitation in nuclear MR.
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FSfor each CMR by voxel and algorithm are shown in Table 1. In
general, these were higher for NAA/Cr but lower for Cho/Cr and
mI/Cr quantiﬁed by TARQUIN. Furthermore, CoVs were gen-
erally consistent across voxels for NAA/Cr and Cho/Cr
quantiﬁed by both algorithms. However, mI/Cr showed con-
siderably more variation than the other two CMRs, particularly
when quantiﬁed using jMRUI. Pearson’s correlation coefﬁcients
for CMR values are shown in Table 2.
Table 2. Pearson’s correlations of cerebral metabolite ratios by region (includes Day 0 and Day 14 data)
CMR
Frontal white matter (n5 22) Frontal grey matter (n5 20) Right basal ganglia (n5 22)
r p-value r p-value r p-value
NAA/Cr 0.74 ,0.01 0.15 0.53 0.38 0.08
Cho/Cr 0.61 ,0.01 0.37 0.11 0.25 0.26
mI/Cr 0.22 0.34 0.41 0.07 20.10 0.66
Cho, choline; CMR, cerebral metabolite ratio; Cr, creatine; mI, myo-inositol; NAA, N-acetylaspartate.
Table 3. Longitudinal changes in cerebral metabolite ratio parameters
Parameter
mean (SD)
Day
0 (n5 11)
Day
14 (n5 11)
Change over
study period
p-value for change over
study period
TARQUIN
Frontal grey matter
NAA/Cr 1.13 (0.21) 1.16 (0.20) 0.03 (0.15) 0.88
Cho/Cr 0.19 (0.033) 0.20 (0.025) 0.01 (0.025) 0.42
mI/Cr 0.75 (0.17) 0.68 (0.19) 20.07 (0.14) 0.17
Frontal white matter
NAA/Cr 1.25 (0.26) 1.25 (0.24) 0.00 (0.27) 0.83
Cho/Cr 0.28 (0.045) 0.30 (0.068) 0.02 (0.076) 0.22
mI/Cr 0.91 (0.28) 0.97 (0.23) 0.06 (0.27) 0.23
Right basal ganglia
NAA/Cr 1.41 (0.24) 1.51 (0.21) 0.10 (0.14) 0.18
Cho/Cr 0.28 (0.033) 0.28 (0.034) 0.00 (0.060) 0.91
mI/Cr 0.76 (0.27) 0.71 (0.28) 20.05 (0.35) 0.61
jMRUI16
Frontal grey matter
NAA/Cr 1.75 (0.19) 1.72 (0.20) 20.02 (0.21) 0.74
Cho/Cr 0.66 (0.10) 0.67 (0.47) 0.02 (0.14) 0.73
mI/Cr 0.64 (0.33) 0.65 (0.01) 0.01 (0.63) 0.96
Frontal white matter
NAA/Cr 1.76 (0.20) 1.77 (0.19) 0.01 (0.19) 0.99
Cho/Cr 1.05 (0.22) 1.05 (0.18) 0.00 (0.23) 0.98
mI/Cr 1.09 (0.65) 1.25 (0.55) 0.17 (0.65) 0.41
Right basal ganglia
NAA/Cr 1.82 (0.39) 2.09 (0.31) 0.27 (0.61) 0.18
Cho/Cr 0.78 (0.12) 0.92 (0.24) 0.14 (0.23) 0.07
mI/Cr 0.69 (0.50) 0.93 (0.48) 0.24 (0.60) 0.17
Cho, choline; Cr, creatine; jMRUI, java-based version of the MR user interface; mI, myo-inositol; NAA, N-acetylaspartate; SD, standard deviation;
TARQUIN, totally automatic robust quantitation in nuclear MR.
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Longitudinal changes in cerebral metabolite ratios
Table 3 shows the results of the baseline (study entry) and Day
14 (post-antiretroviral intensiﬁcation) CMRs. In the three voxels
analysed, no signiﬁcant changes were observed in any of the
CMRs over the study period using either quantiﬁcation method.
Associations between pharmacokinetic results and
cerebral metabolite ratios
Utilizing TARQUIN, the mI/Cr ratio in the RBG on Day 14 was
negatively correlated with trough maraviroc plasma concentra-
tion (Cmin; r520.60, p5 0.049) but not with maraviroc CSF
concentration (r5 0.47, p5 0.15). No signiﬁcant associations
between maraviroc Cmin or CSF concentration with other CMR
changes were observed (p. 0.08 all values, data not shown) or
associations between Day 14 metabolite results and either
plasma or CSF maraviroc concentration. In a previous publi-
cation utilizing jMRUI,16 the only signiﬁcant association was
a positive correlation of NAA/Cr ratio in the RBG with plasma
maraviroc Cmin (r5 0.61, p5 0.047).
DISCUSSION
In this report, 1H-MRS data from HIV-infected patients on
a stable antiretroviral regimen were analysed using two quanti-
ﬁcation models: jMRUI and TARQUIN. This is the ﬁrst report
to compare these particular software packages with regard to
CMRs in HIV-positive subjects. We observed differences be-
tween CMRs, determined by jMRUI and TARQUIN, in all brain
areas, which were most marked for Cho/Cr.
In a previous report describing CMRs quantiﬁed using the
LCmodel in HIV disease at a higher magnetic ﬁeld strength than
our study,24 mean CMRs in the FWM were 1.28, 0.32 and 0.56
for NAA/Cr, Cho/Cr and mI/Cr, respectively. These values are
similar to our ﬁndings in the FWM utilizing the TARQUIN
package (1.25, 0.28 and 0.91 for NAA/Cr, Cho/Cr and mI/Cr,
respectively) and differed to our ﬁndings utilizing the jMRUI
package (1.76, 1.05 and 1.05 for NAA/Cr, Cho/Cr and mI/Cr,
respectively).16 In view of this, we hypothesise the Cho/Cr and
mI/Cr ratios reported in our study, quantiﬁed by TARQUIN,
may be a more accurate reﬂection of the true concentrations of
these metabolites. However, in other studies where the LCmodel
model for spectra quantiﬁcation had been used, different spec-
tral acquisition parameters were utilized. This limits our ability
to determine actual values for these cerebral metabolites.
Our data determined by the TARQUIN package show less var-
iability than those with jMRUI for measurements of mI/Cr. A
possible explanation for this is that TARQUIN is fully automated
and therefore analysed spectra are not dependent on user
interaction. Manual removal of water peaks and the re-
duction of residual MRS noise in jMRUI are user dependent
and could affect quantiﬁcation of spectra and reproducibility
of results.
We also assessed longitudinal 1H-MRS data. No statistically
signiﬁcant longitudinal changes in CMR were evident when
analysed using TARQUIN or jMRUI. We did observe a negative
correlation between mI/Cr ratio measured by TARQUIN with
higher maraviroc plasma Cmin. We hypothesize that this effect
may be secondary to an anti-inﬂammatory property of mar-
aviroc mediated by antagonism by CCR5 or by suppression of
residual HIV replication.25 However, such observations need to
be interpreted with caution given the multiple comparisons and
that our study is a descriptive analysis rather than one with
a sample size powered to determine such observations. This
association was not observed using jMRUI. Although this may
be due to chance and the lack of power we have to make such
observations, another possible explanation is due to the higher
CoV of mI/Cr when measured by jMRUI.
In summary, we have observed that CMRs in HIV-positive
subjects differ when quantiﬁed utilizing jMRUI and TARQUIN.
However, we did not observe signiﬁcant differences in the
clinical associations with CMRs using the two different software
packages giving some conﬁdence to future researchers if they
wished to adopt the newer TARQUIN package. Future work to
assess the accuracy, reproducibility and clinical associations of
CMRs measured via 1H-MRS in HIV-positive subjects is
warranted.
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